{"id":"iopamidol-370-mgi-ml","safety":{"commonSideEffects":[{"rate":null,"effect":"Contrast-induced nephropathy"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Flushing and warmth sensation"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200932","moleculeType":"Small molecule","molecularWeight":"777.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iopamidol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. It distributes throughout the vascular system and extracellular space, allowing visualization of blood vessels, organs, and anatomical structures during angiography, CT, and other imaging studies. The non-ionic formulation reduces osmolality compared to ionic contrast agents, lowering the risk of adverse reactions.","oneSentence":"Iopamidol is a non-ionic iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:05.521Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contrast enhancement for angiography and vascular imaging"},{"name":"Contrast enhancement for computed tomography (CT) imaging"},{"name":"Contrast enhancement for urography and other radiographic procedures"}]},"trialDetails":[{"nctId":"NCT00292487","phase":"PHASE4","title":"Patients With Renal Impairment Undergoing CT","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2004-11","conditions":"Contrast Induced Nephropathy","enrollment":150},{"nctId":"NCT00289029","phase":"PHASE4","title":"A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2005-07","conditions":"CIN","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Iopamidol 370 mgI/mL","genericName":"Iopamidol 370 mgI/mL","companyName":"Bracco Diagnostics, Inc","companyId":"bracco-diagnostics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iopamidol is a non-ionic iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}